Actively Recruiting
Evaluating Safety and Activity of Cevostamab Alone or with Pomalidomide and Dexamethasone or Daratumumab and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma
Led by Genentech, Inc. · Updated on 2026-10-20
186
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, how the body processes pharmacokinetics, and effects pharmacodynamics of the drug cevostamab alone and in combination with other medications in participants with relapsed or refractory multiple myeloma. This is an open-label Phase Ib trial that aims to understand how cevostamab works and its safety when given with pomalidomide and dexamethasone or daratumumab and dexamethasone. The study enrolls adults with this form of multiple myeloma who have had prior treatments. Participants receive cevostamab intravenously on different schedules depending on their assigned group. One group receives cevostamab alone in 28-day cycles with a modified weekly schedule. Another group receives cevostamab plus pomalidomide taken orally and dexamethasone on a two-week then four-week cycle schedule. A third group receives cevostamab with daratumumab administered subcutaneously and dexamethasone on 21-day cycles initially, then 28-day cycles later. Tocilizumab may be given if needed to treat certain side effects. Treatment duration varies by group, with some participants having options to continue or re-treat under specified conditions. Throughout the study, participants undergo various assessments including bone marrow biopsies and blood tests to monitor safety, treatment response, and drug levels. Researchers track dose adjustments, side effects, and response rates up to approximately four years. The study also monitors survival outcomes and immune responses. Participants health and disease status are regularly evaluated during and after treatment to gather comprehensive data about the investigational therapies.
CONDITIONS
Brief Title
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Research Team
R
Reference Study ID Number: GO42552 https://forpatients.roche.com/No attachments to email below.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here